In conclusion, our analysis from a large population‐based study highlights blood apoE4 levels as a potentially modifiable risk factor for cognitive impairment and could support the development of novel strategies that target individuals who carry the APOE ε4 risk gene for AD. Here, APOE is linked to Cognitive impairment.